Experimental and Therapeutic Medicine Special Issues
New strategy and technology following surgical resection.
Lead Editor:
-
Mr Norikatsu Miyoshi
Osaka University
Japan
In recent years, the new strategy and technology are reported very effective, such as liquid biopsy (cfDNA/ctDNA), NGS, artificial intelligence, and minimally invasive surgery (robotic/laparoscopic surgery, and regenerative medicine, in order to improve the patients' QOL after radical surgery. Here, we introduce and discuss these new strategy and technology supposed after surgical resection, and the future.
Submission deadline: 04 July 2024
Immuno-Dermatology
Lead Editor:
-
Dr Rui-Qun Qi
The First Hospital of China Medical University
China
There are more than 2000 kinds of skin diseases. Immune factors affect the occurrence and development of many diseases. In recent years, immunization related biological agents, represented by monoclonal antibodies, have achieved amazing results in clinical treatment. Physical treatments such as light and hyperthermia have been found to clearly induce anti infection immunity, which has the potential to replace previous trauma treatment, bring better non-invasive treatment experience to patients, and significantly reduce the recurrence rate. Basic and clinical immunology related to immune dermatosis has become a research hotspot, and will have a more far-reaching impact on diagnosis and treatment in the future.
Submission deadline: 01 December 2024
Experimental target biomarkers for oral diseases diagnosis and treatment
Lead Editor:
-
Professor Gaetano Isola
University of Catania
Italy
Nowadays, with the development of new and highly sensitive, blood is not the only medium of choice for the diagnosis of several diseases and pathological conditions. Saliva and related oral biomarkers are now considered a safe and non-invasive sample to study oral and systemic diseases, showing great diagnostic potential. According to several recent studies, saliva has emerged as an emerging biofluid for the early diagnosis of several diseases, indicated as a mirror of oral and systemic health and a valuable source of clinically relevant information. Indeed, several studies have observed that saliva is useful for detecting and diagnosing malignant tumours, human immunodeficiency virus, heart disease, and autoimmune diseases. The growing realisation that saliva is an inexhaustible source of information has led to the coining of the term ‘Salivaomics’, which includes five “omics” in connection with the main constituents of saliva: genome and epigenome, transcriptomics, metabolomics, lipidomics, proteomics and microbiota. All those may be changed by disease state, so they offer significant advantages in the early diagnosis and prognosis of oral diseases. The aim of the present special issue is to update and highlight the new frontiers of salivaomics and related oral biomarkers in diagnosing and managing oral disorders, such as periodontitis, premalignant disorders, and oral squamous cell carcinoma (OSCC).
Submission deadline: 01 December 2024
Preeclampsia and Eclampsia, Biochemical mechanisms of Pathophysiology. Prediction,diagnosis and management.
Lead Editor:
-
Dr Panagiotis Peitsidis
Rea Maternity Hospital
Greece
Dear Colleagues, Preeclampsia and Eclampsia are serious hypertensive disorders of pregnancy.These clinical entities are diagnosed after 20 weeks of gestation and may affect many organs such as , liver,kidneys,brain etc. The mechanisms that trigger these conditions are not fully understood however the role of placenta is crucial and several mechanisms of development of hypertensive disease have been proposed. Prediction,diagnosis and management is a difficult task that may require a multidisciplinary clinical approach by several specialties. In this issue we welcome Narrative reviews,Systematic reviews, Mini-reviews,Observational,Experimental studies regarding Preeclampsia and Eclampsia. Emphasis is given in mechanisms of development biochemical,molecular,genetic; in the prediction,diagnosis and management. Furthermore the cardinal topic of future directions should be discussed.
Submission deadline: 01 December 2024
Air Pollution Exposure and Respiratory Diseases
Lead Editor:
-
Professor Elizabeth C Matsui
the University of Texas at Austin
United States
The respiratory system, as the first point of contact with inhaled pollutants, is uniquely vulnerable and eventually reveals signs and symptoms if abnormal. Around 90% of the population worldwide breathes in the air with pollution, consisting of harmful or poisonous substances in outdoor or indoor air. The indoor air quality may be even more important than outdoor quality because of exposure time to pollution. Air pollution is the cause and aggravating factor of many respiratory diseases like chronic obstructive pulmonary disease (COPD), asthma, and lung cancer. In general, children and the elderly are considered more susceptible to air pollution effects than other groups. PM2.5 particulates and metallic elements are also known to contribute to health diseases. Both short-term and long-term exposure to air pollutants were associated with respiratory diseases. Individual exposures depend on many time- and location-specific impact factors, including pollutant type, pollutant concentration in the air, indoor sources, and second-hand smoke. In addition, many studies have shown that people can reduce their susceptibility to pollution through air filters, face masks, medical or chemoprevention methods. Recently, most multi-omics studies have focused on the relationship between environmental exposures and human health, assessing and measuring advances in DNA methylation, microRNA expression and proceeding in epigenetic regulation, protein expression, and metabolic effects. However, the results are still not fully established. Therefore, this special issue encourages potential authors to identify novel environmental risk factors, provide more evidence on the effects of harmful environmental exposures on respiratory diseases, and explore the underlying mechanisms between them, by collecting large samples of longitudinal cohorts, national-representative data, or well-conducting clinical trials. Laboratory, epidemiological and modeling studies on the effects of environmental exposure on respiratory diseases are also welcome. We aim to provide more evidence on the causal relationships between air pollution exposures and respiratory diseases.
Submission deadline: 11 November 2024
The future of microbiota in human diseases: from diagnosis to treatments
Lead Editor:
-
Professor Amedeo Amedei
University of Florence
Italy
The microbiota, the trillions of microorganisms that live on and in humans, as well as the roles they may play in nutrition, sickness, cancer, and even brain development, have sparked a surge of interest in the last decade. Many scientists want to learn more about the microbiota so that we can use it to well define the pathogenesis of more human diseases and to improve the health. But different questions are currently open: how do we get there, and what challenges will we face along the way? What does microbial research have in store for the future? What is the future of microbiome research? What has to be done in order for this field to fulfil its potential? The idea of this special issue is to explore the innovative studies regarding the impacting role of microbiota in several human diseases and also its therapeutic approaches
Submission deadline: 16 August 2024
Novel advances in Interstitial Lung Diseases: From translational research to patient-centered care
Lead Editor:
-
Dr KATERINA ANTONIOU
university of crete
Greece
ILDs are including mainly fibrotic chronic lung diseases affecting predominantly older adults, with a history of smoking. The current model of disease natural course is that recurrent injury of the alveolar epithelium in the context of advanced aging/cellular senescence is followed by defective re-epithelialization and scar tissue formation. Currently, two drugs, nintedanib and pirfenidone, that modify disease progression have been approved worldwide for the treatment of IPF. However, despite treatment, patients with fibrosis are not cured, and eventually, disease advances in most treated patients. Enhancing biogenomic and metabolic research output, its translation into clinical precision and optimal service delivery through patient-centeredness are key elements to support effective IPF care. In this issue, we will summarize therapeutic options currently investigated for fibrosis and sarcoidosis based on the major pathogenetic pathways and molecular targets that drive pulmonary fibrosis.
Submission deadline: 31 July 2024
Malignant transformation induced by environmental substances in several types of experimental cancer
Lead Editor:
-
Dr Gloria m Calaf
Universidad de Tarapaca. Instituto de Alta Investigacion
Chile
The interaction of chemical carcinogens with healthy cells associated with exogenous hormones can induce genomic damage and subsequently cause cancer with the ability of metastasize other tissues. The carcinogenesis process needs several mutational events to produce damage to the genome, and subsequent cell proliferation of these injured cells. DNA damage can be the result of interactions with exogenous agents such as chemical carcinogens. Examples are the organophosphorous pesticides that are chemical substances synthesized by men and mainly used for pest control in agriculture and residential urban surroundings. On the other hand, the estrogen 17β-estradiol is an endogenous hormone present in women that influences development, control of ovulation, implantation, fertilization and metabolism of minerals, carbohydrates, proteins and lipids. The production of endogenous estrogen ceases with menopause and there is a controversy concerning its use in hormone replacement therapy. There is strong epidemiological and clinical evidence that estrogens play a role in the induction, promotion and progression of a variety of cancers in target organs of rat, mice and hamster. Other studies have associated estrogen administration to postmenopausal women with an increased risk of endometrial and breast cancer. It will be of interest to put together information in relation to this subject in different types of cancers and the future avenue to understand mechanism to obtain new treatments.
Submission deadline: 25 July 2024
Translational research, techniques and innovation in GI endoscopy
Lead Editor:
-
Dr Hajime Isomoto
Department Gastroenterology and Nephrology, Tottori University
Japan
Recent advancement in GI endoscopic diagnostic yield and interventions has been outstanding by involvement by AI technology, robotics, innovative conceptions. Whilst, the invention has been supported by case series experience by experts even in certain sole case technical success or by translational research using animal models or basic research using the state-of-art technologies including omics. In this specific issues, we propose submission of full original communications related to topics above mentioned while case series experiences or informative case success if authors discuss potential prevalence of the novel techniques expanding to real world practice, insightful contrivance, or innovative concept that would open the door for breakthrough and foreseeable future perspective.
Submission deadline: 06 July 2024
Obesity related ailments: recent non invasive treatments
Lead Editor:
-
Professor Marilena Vlachou
National and Kapodistrian University of Athens
Greece
Obesity is a disease that leads to significant co-morbidities such as diabetes, fatty liver and cardiovascular disease, and significantly shortens a person's life expectancy and quality of life. There is a need for safer and more effective treatments for obesity, such as innovative drug delivery systems, vaccines, gut microbiota modification, and gene therapy. Novel delivery systems may include 3D printing technologies and the application of AI approaches. Novel drugs, such as combinations of gastrointestinal hormones and other agents, are being explored and, when available, are expected to lead to significant weight loss with fewer side effects.
Submission deadline: 30 June 2024
